Atorvastatin prevents advanced glycation end products (AGEs)-induced cardiac fibrosis via activating peroxisome proliferator-activated receptor gamma (PPAR-γ)

Metabolism: Clinical and Experimental

Volumn 65, Issue 4, 2016, Pages 441-453

  Chen, Miao ^a   Li, Hongwei ^a   Wang, Guoxing ^a   Shen, Xuhua ^a   Zhao, Shumei ^a   Su, Wen ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Atorvastatin; PPAR ; RAGE

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CHLORO 5 NITROBENZANILIDE; ADVANCED GLYCATION END PRODUCT; ALPHA SMOOTH MUSCLE ACTIN; ATORVASTATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; 2-CHLORO-5-NITROBENZANILIDE; ACTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, RAT; ANILIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SMOOTH MUSCLE ACTIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; HEART FIBROBLAST; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICALLY INDUCED; DOWN REGULATION; DRUG EFFECTS; ECHOGRAPHY; FIBROSIS; HEART DISEASES; HEART FUNCTION TEST; METABOLISM; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ACTINS; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANILIDES; ANIMALS; ATORVASTATIN CALCIUM; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; FIBROSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART DISEASES; HEART FUNCTION TESTS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MAP KINASE SIGNALING SYSTEM; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84960361126     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.11.007     Document Type: Article

References (56)

1. J. Asbun, and F.J. Villarreal The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy J Am Coll Cardiol 47 2006 693 700
2. B. Hinz, S.H. Phan, V.J. Thannickal, A. Galli, M.L. Bochaton-Piallat, X.L. Deng, and G. Gabbiani The myofibroblast: One function, multiple origins Am J Pathol 170 2007 1087 1816
3. L. Van Heerebeek, N. Hamdani, M.L. Handoko, I. Falcao-Pires, R.J. Musters, K. Kupreishvili, and et al. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension Circulation 117 2008 43 51
4. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
5. M. Tang, M. Zhong, Y. Shang, H. Lin, J. Deng, H. Jiang, and et al. Differential regulation of collagen types I and III expression in cardiac fibroblasts by AGEs through TRB3/MAPK signaling pathway Cell Mol Life Sci 65 2008 2924 2932
6. A.L. Tan, J.M. Forbes, and M.E. Cooper AGE, RAGE, and ROS in diabetic nephropathy Semin Nephrol 27 2007 130 143
7. O. Hori, J. Brett, T. Slattery, R. Cao, J. Zhang, J.X. Chen, and et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system J Biol Chem 270 1995 25752 25761
8. Juan Asbun, and J. Francisco Villarreal The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy JACC 47 2006 693 700
9. Sang-Hyun Ihm, Kiyuk Chang, Hee-Yeol Kim, S.H. Baek, H.J. Youn, K.B. Seung, and et al. Peroxisome proliferator-activated receptor-c activation attenuates cardiac fibrosis in type 2 diabetic rats: The effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor Basic Res Cardiol 105 2010 399 407
10. T. Yoshida, S. Yamagishi, K. Nakamura, T. Matsui, T. Imaizumi, M. Takeuchi, and et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferators activated receptor activation Diabetologia 49 2006 3094 3099
11. A.L. Tan, J.M. Forbes, and M.E. Cooper AGE, RAGE, and ROS in diabetic nephropathy Semin Nephrol 27 2007 130 143
12. Li-Mei Zha, Wei Zhang, Li-Ping Wang, G.R. Li, and et al. Advanced glycation end products promote proliferation of cardiac fibroblasts by upregulation of KCa3.1 channels Eur J Physiol 464 2012 613 621
13. S.I. McFarlane, R. Muniyappa, R. Francisco, J.R. Sowers, and et al. Pleiotropic effects of statins: Lipid reduction and beyond J Clin Endocrinol Metab 87 2002 1451 1458
14. S.P. Zhao, and D.Q. Zhang Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits Clin Chim Acta 336 2003 103 108
15. G.A. Francis, J.S. Annicotte, and J. Auwerx PPAR agonists in the treatment of atherosclerosis Curr Opin Pharmacol 3 2003 186 191
16. Yumei Ye, P. Shawn, C. Nishi, Saraswathy Manickavasagam, Y. Lin, M.H. Huang, J.R. Perez-Polo, and et al. Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2 Prostaglandins Other Lipid Mediat 84 2007 43 53
17. L. Han, M. Li, Y. Liu, C. Han, P. Ye, and et al. Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats Pharmacology 89 2012 74 82
18. Melinda T. Coughlan, Felicia Y.T. Yap, David C.K. Tong, S. Andrikopoulos, A. Gasser, V. Thallas-Bonke, and et al. Advanced glycation end products are direct modulators of β-cell function Diabetes 60 2011 2523 2532
19. C. Kumaran, and K. Shivakumar Calcium and superoxide anion-mediated mitogenic action of substance P on cardiac fibroblasts Am J Physiol Heart Circ Physiol 282 2002 1855 1862
20. Huasheng Liang, Yuhua Zhong, Shaobi Zhou, and Peng Liang Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo Cancer Lett 313 2011 91 98
21. W.B. Melenhorst, G.M. Mulder, Q. Xi, and et al. Epidermal growth factor receptor signaling in the kidney: Key roles in physiology and disease Hypertension 52 2008 987 993
22. L. Xu, P. Zang, B. Feng, Q. Qian, J.G. Hoenderop, K. Kimura, and S. Eguchi Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats Diabetol Metab Syndr 6 1 2014 102 111
23. H. Akahori, T. Tsujino, Y. Naito, M. Matsumoto, N. Sasaki, T. Iwasaku, and et al. Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats J Hypertens 32 7 2014 1534 1541
24. J. Quidgley, N. Cruz, and M.J. Crespo Atorvastatin improves systolic function, but does not prevent the development of dilated cardiomyopathy in streptozotocin-induced diabetic rats Ther Adv Cardiovasc Dis 8 4 2014 133 144
25. P.F. Castro, R. Miranda, H.E. Verdejo, D. Greig, L.A. Gabrielli, H. Alcaino, and et al. Pleiotropic effects of atorvastatin in heart failure: Role in oxidative stress, inflammation, endothelial function, and exercise capacity J Heart Lung Transplant 27 4 2008 435 441
26. Doron Aronson Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes J Hypertens 21 2003 3 12
27. V. Salomaa, W. Riley, J.D. Kark, C. Nardo, and A.R. Folsom Non-insulin dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study Circulation 91 1995 1432 1443
28. V.L. Bodiga, S.R. Eda, and S. Bodiga Advanced glycation end products: Role in pathology of diabetic cardiomyopathy Heart Fail Rev 19 2014 49 63
29. M. Montagnani Diabetic cardiomyopathy: How much does it depend on AGE? Br J Pharmacol 154 2008 725 726
30. J. Nozynski, M. Zakliczynski, D. Konecka-Mrowka, B. Nikiel, J. Mlynarczyk-Liszka, E. Zembala-Nozyńska, and et al. Advanced glycation end products in the development of ischemic and dilated cardiomyopathy in patients with diabetes mellitus type 2 Transplant Proc 41 2009 99 104
31. L. van Heerebeek, A. Somsen, and W.J. Paulus The failing diabetic heart: Focus on diastolic left ventricular dysfunction Curr Diab Rep 9 2009 79 86
32. B.K. Kilhovd, T.J. Berg, K.I. Birkeland, P. Thorsby, and K.F. Hanssen Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease Diabetes Care 22 1999 1543 1548
33. H.J. Huttunen, C. Fages, and H. Rauvala Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappa B require the cytoplasmic domain of the receptor but different downstream signaling pathways J Biol Chem 274 1999 19919 19924
34. Y.U.A.N. Xiaochen, Z.H.A.N.G. Zhengang, G.O.N.G. Kaizheng, Z.H.A.O. Pei, Q.I.N. Jianhua, and L.I.U. Naifeng Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats Biol Pharm Bull 34 5 2011 618 623
35. F. Blanchette, N. Rivard, P. Rudd, F. Grondin, L. Attisano, and C.M. Dubois Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor beta1-induced furin gene transactivation J Biol Chem 276 2001 33986 33994
36. M. Neeper, A.M. Schmidt, J. Brett, S.D. Yan, F. Wang, Y.C. Pan, and et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins J Biol Chem 267 1992 14998 15004
37. Zeinab Hegab, Stephen Gibbons, Ludwig Neyses, and Mamas A. Mamas Role of advanced glycation end products in cardiovascular disease World J Cardiol 26 4 2012 90 102
38. M. Pertynska-Marczewska, E. Diamanti-Kandarakis, J. Zhang, Z. Merhi, and et al. Advanced glycation end products: A link between metabolic and endothelial dysfuncti-on in polycystic ovary syndrome? Metabolism 64 11 2015 1564 1573
39. W.F. Owen Jr., F.F. Hou, R.O. Stuart, J. Kay, J. Boyce, G.M. Chertow, and et al. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts Kidney Int 53 1998 1365 1373
40. San-Cher Chen, Jinn-Yuh Guh, Chi-Ching Hwang, S.J. Chiou, T.D. Lin, Y.M. Ko, and et al. Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts J Cell Biochem 109 2010 38 48
41. D. Loch, S. Levick, A. Hoey, and L. Brown Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats J Cardiovasc Pharmacol 47 2006 396 404
42. H. Akahori, T. Tsujino, Y. Naito, M. Matsumoto, N. Sasaki, T. Iwasaku, and et al. Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats J Hypertens 32 7 2014 1534 1541
43. M. Saka, K. Obata, S. Ichihara, X.W. Cheng, H. Kimata, T. Nishizawa, and et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure J Cardiovasc Pharmacol 47 2006 770 779
44. M. Saka, K. Obata, S. Ichihara, X.W. Cheng, H. Kimata, A. Noda, and et al. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: Potential role of the RhoA-extracellular signal-regulated kinase serum response factor signalling pathway Clin Exp Pharmacol Physiol 33 2006 1164 1171
45. S. Ichihara, A. Noda, K. Nagata, K. Obata, J. Xu, G. Ichihara, and et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure Cardiovasc Res 69 2006 726 735
46. Bo Feng, Lei Xu, Hua Wang, X. Yan, J. Xue, F. Liu, and et al. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products Biochim Biophys Acta 1812 9 2011 1130 1137
47. Nitin Mahajan, Ajay Bahl, and Veena Dhawan C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: Inhibitory effects of atorvastatin Int J Cardiol 142 2010 273 278
48. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor activation Biochem Biophys Res Commun 385 2009 269 272
49. Ou. Zhang, and Jinying Zhang Atorvastatin promotes human monocyte differentiation toward alternative M2 macrophages through p38 mitogen-activated protein kinase-dependent peroxisome proliferator-activated receptor γ activation Int Immunopharmacol 26 2015 58 64
50. Miyuki Yano, Takeshi Matsumura, Takafumi Senokuchi, N. Ishii, Y. Murata, K. Taketa, and et al. Statins activate peroxisome proliferator-activated receptor through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages Circ Res 100 2007 1442 1451
51. P. Ye, L. Sheng, C. Zhang, and Y. Liu Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo J Pharm Pharm Sci 9 2006 365 375
52. Byung Chul Park, Dinesh Thapa, Jong Suk Lee, S.Y. Park, J.A. Kim, and et al. Troglitazone inhibits vascular endothelial growth factor-induced angiogenic signaling via suppression of reactive oxygen species production and extracellular signal-regulated kinase phosphorylation in endothelial cells J Pharmacol 111 2009 1 12
53. Dengfeng Gao, Guanghua Hao, Zhe Meng, N. Ning, G. Yang, Z. Liu, and et al. Rosiglitzone suppresses angiotensin II induced production of KLF5 and cell proliferation in rat vascular smooth muscle cells PLoS One 10 4 2015 e0123724
54. Lu. Yu, Yanbo Zhao, Shengjie Xu, F. Ding, C. Jin, G. Fu, and et al. Advanced glycation end product (AGE)-AGE receptor (RAGE) system upregulated Connexin43 expression in rat cardiomyocytes via PKC and ERK MAPK pathways Int J Mol 14 2013 2242 2257
55. Yuhuang Li, Shuying Liu, Zhengyu Zhang, Q. Xu, F. Xie, J. Wang, and et al. RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation PLoS One 7 4 2012 e35016
56. X. Yuan, and N. Liu Pioglitazone suppresses advanced glycation end product-induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells J Genet Genomics 38 5 2011 193 200